The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that represent a formidable obstacle to the successful treatment of cancer. Patients with high frequencies of MDSCs have significantly decreased progression-free survival (PFS) and overall survival (OS). Whereas there is experimental evidence that the reduction of the number and/or suppressive function of MDSCs in mice improves the efficacy of anti-cancer therapies, there is notably less evidence for this therapeutic strategy in human clinical trials. Here, we discuss currently available data concerning MDSCs from human clinical trials and explore the evidence that targeting MDSCs may improve the efficacy of cancer therapies.
Department of Surgery, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA; and.
Richard P
RP
Tobin
Department of Surgery, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA; and.
Dana
D
Davis
Department of Immunology and Microbiology, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.
Kimberly R
KR
Jordan
Department of Surgery, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA; and martin.mccarter@ucdenver.edu.
Martin D
MD
McCarter
D006801:Humans; D000072737:Myeloid-Derived Suppressor Cells / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D019139:Tumor Escape / Q000276:immunology*
MDSC; immunosuppression; immunotherapy; oncology